Search - tctmd.com

Displaying 1 - 1 of 1

Sort: Relevancy | Date

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

Country

First Name

Last Name

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.